Stock screener

EXEL

Conviction 100HealthcareScan · Thu, Jun 25, 2026
EXEL$53.22+0.66%
ResistanceSupportVol 14Insider sell
63 bars
2
2
3
Vol MA14 2.92M
Mar 26Apr 14May 1May 19Jun 8Jun 25
EXELIXIS, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.exelixis.com
Price53.22
Change+0.66%
Gap-0.32%
Rel volume2.70×
Avg volume2.91M
Avg $ vol151.36M
SMA 2051.99
SMA 5049.09
SMA 20043.78
Price vs 50+8.41%
Price vs 200+21.56%
MA stackbullish
50/200 cross
Supertrendup · 48.98
RSI (14)60
MACD hist-0.17
MACD crossbear · 6d
Stoch %K / %D77 / 66
ADX (14)25
+DI / −DI21 / 14
RSI divergenceBearish
MACD divergence
ATR %+2.97%
ADR %3.12%
52w high53.50
52w low34.54
From 52w high-0.52%
Above 52w low+54.08%
New 52w highNo
SqueezeOff
Bollinger width9.05%
%B0.76
Donchian pos87.81%
Donchian high53.93
Donchian low48.10
AVWAP (52w high)52.42
vs AVWAP high+1.53%
AVWAP (52w low)44.23
vs AVWAP low+20.33%
OBV trendFlat
Chaikin MF (20)-0.03
Today vs 20d2.70×
Avg vol (14d)2.92M
Avg vol (20d)2.91M
Avg $ vol (20d)151.36M
Market cap13.38B
RS 3m (vs SPY)+14.93%
RS 6m (vs SPY)+11.61%
RS line new highNo
Trend template8/8
Technical rank81.3
1 week+1.49%
1 month+6.48%
3 months+24.39%
6 months+15.22%
1 year+16.40%
YTD+22.12%
P/E17.09
P/B6.91
P/S5.77
P/FCF15.27
EPS2.78
Div yield
ROE40.43%
ROA30.17%
Debt/Eq0.10
Current3.26
EV/EBITDA14.80
Gross margin8.25%
Net margin33.73%
Rev growth6.98%
EPS growth50.13%
Price target48.10
Target upside-9.62%
Analyst ratingHold
Institutional114.81%
Ent. value13.34B
Revenue610.81M
Net income210.47M
Gross profit
Free cash flow875.84M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out251.36M
Employees1.08K
ListedTue, Apr 11, 2000
Free float251.4M
Float %96.8%
Short interest29.71M
Days to cover12.3d
Short volume62.7%
Squeeze score79 / 100
Next earningsMon, Jul 27, 2026 (32d)
EPS forecast$0.75 · 4 est
Last EPS vs est$0.79 vs $0.67
Last surprise+17.9% beat
Setup gradeA+
Conviction100 / 100
Pattern quality
Tech rank81.3 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance53.45
Support43.50
Days since event
Candle confirm
News sentiment

Financials as of Fri, Apr 3, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in EXEL

All disclosures →
No recent disclosed trades by Congress in EXEL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in EXEL · 8 buys · 2 sells

InsiderSideShares
WYSZOMIERSKI JACK L
Director · Common Stock · 2026-06-01
Sell3.92K
Eckhardt Sue Gail
Director · Common Stock · 2026-06-01
Sell9.81K
Smith Julie
Director · Common Stock · 2026-05-27
Grant8.37K
PAPADOPOULOS STELIOS
Director · Common Stock · 2026-05-27
Grant8.37K
POSTE GEORGE
Director · Common Stock · 2026-05-27
Grant8.37K
JOHNSON DAVID EDWARD
Director · Option (right to buy) · 2026-05-27
Grant19.13K
Eckhardt Sue Gail
Director · Common Stock · 2026-05-27
Grant8.37K
Freire Maria C
Director · Common Stock · 2026-05-27
Grant8.37K
Oliver Bob
Director · Common Stock · 2026-05-27
Grant8.37K
Heyman Tomas J.
Director · Common Stock · 2026-05-27
Grant8.37K

SEC filings

EDGAR filings in EXEL · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.